SRTD Biotech
Agent50Agent Readiness: 50/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust72Data Trust: 72/100. Above median. Measured by StartupHub.ai. Median 61.SRTD Biotech develops next-generation precision mRNA therapeutics targeting diseased cells.
About
Founded in 2019, SRTD Biotech is an integrated RNA therapeutics company focused on developing cell-specific messenger RNA (mRNA) therapies. Its platform combines proprietary selectively expressed RNA (seRNA) technology, a novel fusogenic LNP delivery platform, and a synthetic biology platform with bioinformatics and AI-driven RNA design capabilities to achieve precise, selective therapeutic activity within target cells while limiting exposure in healthy tissue.
Key facts
- Website
- srtd-biotech.com
- Headquarters
- Jülich, Germany
- Founded
- 2019
- Total funding
- $34M (Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Nov 2026 | Seed | $34M | Mérieux Equity Partners (via OMX Europe Venture Fund), NRW.BANK, Boehringer Ingelheim Venture Fund (BIVF) |
Tech stack
Detected on srtd-biotech.com, last scanned 9 Nov 2026. Run your own scan
- Email provider
- Microsoft 365
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is SRTD Biotech trustworthy and reputable?
StartupHub's Data Trust & Reputation score for SRTD Biotech is 72 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has SRTD Biotech raised?
SRTD Biotech has raised a total of $34M in funding. The most recent round on record is Seed.
SEC filings, insider activity, nonprofit links and pay benchmarks for SRTD Biotech:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
